Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49. RSI readings suggest the stock ...

Natera (NTRA) announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

Natera has begun the subject enrolment in the randomised Phase III SAGITTARIUS clinical trial designed to assess the ...

JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Natera (NTRA) to $200 from $160 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect ...

Sometimes the most under-hyped sectors are the best places to build very large businesses,” said one venture investor who ...

Children's Health?, one of the largest and most prestigious pediatric health care institutions in the country and the leading pediatric health care system in North Texas, opened its ...

CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

Natera, Inc.（纳斯达克股票代码：NTRA）的董事Chapman Rowan ...

德克萨斯州奥斯汀讯——根据向美国证券交易委员会提交的4表格显示，Natera, Inc.（纳斯达克股票代码：NTRA）临床诊断总裁Solomon Moshkevich最近进行了一笔重大的公司股票交易。Moshkevich于2024年12月9日以加权平均价格166.5937美元每股的价格出售了4,858股Natera普通股。此次出售的总价值约为809,312美元。根据 InvestingPro ...

From M&A and tariffs to new health leaders, here are the top issues for the medtech industry to watch when President-elect ...

Request To Download Free Sample of This Strategic Report @- For instance, Genetic testing has been widely used in pharmacogenomics, also referred as drug-gene testing. In addition, advancements in ...